Repositioning Candidate Details
| Candidate ID: | R0742 |
| Source ID: | DB05222 |
| Source Type: | investigational |
| Compound Type: | biotech |
| Compound Name: | KB001 |
| Synonyms: | -- |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | KB001 is a Humaneered™ PEGylated monoclonal antibody fragment for the treatment of life-threatening Pseudomonas aeruginosa infections, a common problem of cystic fibrosis and mechanically ventilated patients. |
| CAS Number: | -- |
| Molecular Weight: | |
| DrugBank Indication: | For the treatment of infections caused by multi-drug resistant <em>Pseudomonas aeruginosa</em>. |
| DrugBank Pharmacology: | KaloBios is developing KB001, a PEGylated engineered human Fab' fragment for the prevention and treatment of <em>Pseudomonas aeruginosa</em> infections. The Fab' fragment is specific for the PcrV antigen, an essential component of the Type III secretion system, a key virulence factor with multiple roles in both infection and pathogenesis. KB001 shows potent activity in mouse models of pulmonary infection, reducing mortality and leading to effective clearance of bacteria from infected lungs. This molecule therefore represents an attractive candidate for clinical evaluation in the prevention or treatment of <em>Pseudomonas</em> infection in Cystic Fibrosis, pneumonia, and other indications. |
| DrugBank MoA: | KB001 targets and neutralizes the PcrV protein of the Type III secretion system of the Pseudomonas bacterium, which directly inhibits its toxic effects. This mechanism of action is different from that of other antibiotics and represents a new approach in the treatment of bacterial infections. |
| Targets: | PcrV |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S03 | Anti-fibrosis | fibrosis | Angiotensin Receptor Blocker (ARB); CCR2/CCR5 antagonist; Thyroid receptor β agonist; PEGylated human FGF21 analogue; Monoclonal antibody to lysyl oxidase-like 2 (LOXL2); Galectin-3 inhibitor; FGF19 variant | Losartan; Cenicriviroc; VK-2809; MGL-3196; Pegbelfermin; Simtuzumab; GR-MD-02; NGM282 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I01 | 552 | Pneumonia | A lung disease that involves lung parenchyma or alveolar inflammation and abnormal alveolar filling with fluid (consolidation and exudation). It results from a variety of causes including infection with bacteria, viruses, fungi or parasites, and chemical or physical injury to the lungs. It is accompanied by fever, chills, cough, and difficulty in breathing. http://en.wikipedia.org/wiki/Pneumonia | disease of anatomical entity/respiratory system disease/ lower respiratory tract disease/lung disease | Details |